TransCode Therapeutics, Inc. (RNAZ): Operating Profitability

Brandmark of TransCode Therapeutics (RNAZ)

Operating profit margin dynamics demonstrate that the indicator value is 0.00. TransCode Therapeutics (RNAZ) is developing RNA therapies against cancer metastases using nanoparticles for drug delivery. However, the absence of commercial products and high research costs negate current profits. The company is currently in a survival mode, limiting external ties to occasional academic grants.

RNAZ: TransCode Operating Margin 07/04/2022 - 11/19/2026

Metric breakdowns and analytics for TransCode Therapeutics (RNAZ)

- share price and consensus valuation forecast:
Basic company analysis:TransCode Therapeutics
Finished products of TransCode

For the non-cyclical biotech TransCode Therapeutics (RNAZ), this indicator serves as a measure of cost-management efficiency for RNA drug development relative to operating income. The ratio of operating profit to revenue, illustrated through the operating margin trend, reveals the business's actual commercial return, confirming its macro-stability and fundamental ability to function independently of GDP fluctuations during clinical trial periods.

Direct competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|CDXS - Operating Sales Margin|Sangamo Therapeutics Inc. - Operating Margin|NAUT - Operating Margin|MGX: Operating Margin|Operating Sales Margin Precision BioSciences, Inc.|GBIO (Generation Bio) - Operating Margin|Boundless Bio Inc. (BOLD) - Profitability of Operations|Operating Sales Margin XCUR (exicuretx.com)|Imunon Inc - Return on Sales by Operating Profit|Operating Margin PHIO (Phio Pharmaceuticals Corp)|Operating Profit Rate MBIO|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability